Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Bringing next-gen cannabinoid therapeutics to cancer patients
The company is now introducing the product into the India pharmaceutical market.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
Subscribe To Our Newsletter & Stay Updated